Seznam všech zadavatelů
Zobrazuji zprávy zadavatele: Merck
Nalezený počet: 41
Merck to Showcase New Data Across MS Portfolio at EAN 2019
24.06.2019 14:34
Darmstadt (Germany) June 24th 2019 (PROTEXT/PRNewswire) - Not intended for UK or U.S. based media - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® ( interferon beta-1a) and investigational evobrutinib at the 5th Congress...
Zadavatel: Merck
Merck Pioneers New Efforts to See MS From the Inside Out
30.05.2019 10:00
Darmstadt (Germany) May 30th 2019 (PROTEXT/PRNewswire) - Not intended for media in the UK and the U.S. ● Company launches global art campaign for people with MS to express their invisible symptoms and the unseen impact of the disease ●...
Zadavatel: Merck
Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton ?s Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
11.05.2019 13:17
Darmstadt (Germany) May 11th 2019 (PROTEXT/PRNewswire) - Not intended for U.S. media 48-week results provide additional evidence of relapse reduction for investigational evobrutinib Evobrutinib demonstrated rapid lesion reductions on MRI at week...
Zadavatel: Merck
Merck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
30.04.2019 14:27
Darmstadt (Germany) April 30th 2019 (PROTEXT/PRNewswire) - Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple...
Zadavatel: Merck
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
1.04.2019 09:20
Darmstadt (Germany) March 29th 2019 (PROTEXT/PRNewswire) - - MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's unique mechanism may provide an important new option...
Zadavatel: Merck
MAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland.
Darmstadt (Germany) March 25th 2019 (PROTEXT/PRNewswire) - - MAVENCLAD ® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a n ovel mechanism for highly active relapsing multiple sclerosis in Switzerland -...
Zadavatel: Merck
World MS Day 2018: Call for Greater Curiosity to Drive Understanding of the Disease and Future Innovation
30.05.2018 09:00
Darmstadt (Germany) May 30th 2018 (PROTEXT/PRNewswire) - - Launch of #MSInsideOut campaign, aimed at providing a deeper understanding of multiple sclerosis (MS) - Donation to the MS International Federation (MSIF)* of up to €20,000 - Shift.ms to Executive...
Zadavatel: Merck
Mavenclad (Cladribine Tablets) Data in Multiple Sclerosis Journal Show an Even Greater Treatment Effect in Patients With Highly Active Multiple Sclerosis
2.05.2018 10:30
Darmstadt (Germany) May 2nd 2018 (PROTEXT/PRNewswire) - - Post-hoc analysis from the 2-year CLARITY study demonstrated that Mavenclad reduced the risk of 6-month EDSS progression by 47% vs placebo - Patients with highly active multiple sclerosis had...
Zadavatel: Merck
Mavenclad (Cladribine Tablets) Receives First Approval in Latin America
27.02.2018 09:28
Darmstadt (Germany) February 27th 2018 (PROTEXT/PRNewswire) - Not intended for U.K./U.S. based media - First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in Argentina - Mavenclad has shown sustained...
Zadavatel: Merck
Společnost Merck získala další dva patenty pro technologii CRISPR
Darmstadt (Německo) 20. února 2018 (PROTEXT/PRNewswire) - - Patenty v Jižní Koreji a Izraeli pokrývají integraci externí sekvence DNA do chromozomu eukaryotických buněk - Společnost Merck pokračuje v podpoře výzkumu úpravy genomu v rámci pečlivých...
Zadavatel: Merck
Vaše tiskové zprávy rozšíříme spolu se zpravodajstvím ČTK uživatelům agenturního servisu jako jsou média, ekonomická sféra, státní správa a veřejnost. Texty zůstávají uloženy v Infobance ČTK, jsou součástí mobilní aplikace ČTK a obdrží je také tisíce odběratelů našeho e-mail servisu. Veřejnosti je zpřístupníme na více než 15 zpravodajských portálech.
Doporučujeme
Slavnostní vyhlášení prestižní soutěže Czech Press Photo 2026